Affinity Bio Partners, AI Health Outcomes and CannaBot will work together to manage research and development projects, clinical studies, assist with patient education, utilization of artificial technology through the CannaBot™ for ARK’s Research and Development efforts within South Africa as well as ARK’s entrance into the United States market.
Collaborations within the Medical Cannabis and CBD Industries Rising from the Ashes: Collaborations within the Medical Cannabis and CBD Industries”...
For Immediate Release: SCICANN THERAPEUTICS, FSD PHARMA, AFFINITY BIO PARTNERS AND COMPASSIONATE CARE CERTIFICATION CENTERS
“SciCann Therapeutics and FSD Pharma announce selection of Affinity Bio Partners as the Clinical Research Organization in connection with Compassionate Care Certification Centers to launch the first clinical research study for Irritable Bowel Syndrome (IBS) in Pittsburgh, PA.”
Learn more at cannabot.ai
Upcoming Proof of Concept Clinical Study on ELYSIUM CBD and Epileptic Patients by Cannavalon Biosciences Inc. Affinity Bio Partners is...
Christina DiArcangelo Puller is an international woman entrepreneur with a world-class reputation in the Biotechnology and Pharmaceutical industry.